NCT06031805 PRostate Olaparib Real World Evidence Study
| NCT ID | NCT06031805 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Metastatic Castration-resistant Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-10-11 |
| Primary Completion | 2028-10-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-10-11 with a primary completion date of 2028-10-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
Eligibility Criteria
* Adult male patients (≥ 18 years old) * with metastatic castration-resistant prostate cancer, * who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program * who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA, * Still alive and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician); * who deceased and who did not object to data collection for research purpose(s) during his or her lifetime. Exclusion criteria * Patients opposed to the collection of their data * Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06031805 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Castration-resistant Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06031805 currently recruiting?
Yes, NCT06031805 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06031805 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Antony, France, Argenteuil, France and 11 additional locations.
Who is sponsoring the NCT06031805 clinical trial?
NCT06031805 is sponsored by AstraZeneca. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.